Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct
In a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients.n a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients. n a two-part series, this first paper outlines the quality and regulatory thinking that underpins RBQM, and details essential points of compliance for emerging ICH core guidances on RBQM—including ICH E8 (R1) and ICH GCP E6 (R3)—and offers further discussion of RBQM implications for sponsors, clinical sites and patients.
Related Insights
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Playbook
Where better medicines begin
Dec 14, 2022
Video
The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?
Feb 1, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Related Insights
Video
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Video
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Article
Decentralized trial tools and technologies are here to stay: A regulatory perspective
Jul 23, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Playbook
Where better medicines begin
Dec 14, 2022
Video
The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?
Feb 1, 2023
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025